A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. by Lou, Jianlong et al.
UCSF
UC San Francisco Previously Published Works
Title
A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of 
Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.
Permalink
https://escholarship.org/uc/item/8sn061q6
Journal
Toxins, 10(2)
ISSN
2072-6651
Authors
Lou, Jianlong
Wen, Weihua
Conrad, Fraser
et al.
Publication Date
2018-02-15
DOI
10.3390/toxins10020084
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
toxins
Article
A Single Tri-Epitopic Antibody Virtually
Recapitulates the Potency of a Combination of Three
Monoclonal Antibodies in Neutralization of
Botulinum Neurotoxin Serotype A
Jianlong Lou 1,*, Weihua Wen 1, Fraser Conrad 1 ID , Qi Meng 1, Jianbo Dong 1, Zhengda Sun 1,
Consuelo Garcia-Rodriguez 1, Shauna Farr-Jones 1 ID , Luisa W. Cheng 2, Thomas D. Henderson 2,
Jennifer L. Brown 3, Theresa J. Smith 3, Leonard A. Smith 4, Anthony Cormier 5 ID and
James D. Marks 1,*
1 Department of Anesthesia and Perioperative Care, University of California, San Francisco Rm 3C-38,
San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA;
weihua.wen@ucsf.edu (W.W.); fraser.conrad@ucsf.edu (F.C.); fanqimeng@gmail.com (Q.M.);
jianbodong@gmail.com (J.D.); zhengda.sun@ucsf.edu (Z.S.); MariaConsuelo.Garcia@ucsf.edu (C.G.-R.);
Shauna.farr-jones@ucsf.edu (S.F.-J.)
2 Western Regional Research Center, Agricultural Research Service, United States Department of Agriculture,
Albany, CA 94710, USA; luisa.cheng@ars.usda.gov (L.W.C.); Thomas.henderson@ars.usda.gov (T.D.H.)
3 Molecular and Translational Sciences Division, United States Army Medical Institute of Infectious Disease,
Fort Detrick, MD 21702, USA; jennifer.l.brown436.ctr@mail.mil (J.L.B.); terrys2much@comcast.net (T.J.S.)
4 U. S. Army Medical Research and Materiel Command, Fort Detrick, MD 21702, USA;
leonard.a.smith@comcast.net
5 Department of Pathology, University of California, San Francisco, ZSFG/UCSF, Bldg 3/ Rm 211,
1001 Potrero Ave., San Francisco, CA 94158, USA; Anthony.Cormier@ucsf.edu
* Correspondence: jianlong.lou@ucsf.edu (J.L.); Jim.Marks@ucsf.edu (J.D.M.);
Tel.: +1-415-206-4137 (J.L.); +1-415-206-3256 (J.D.M.)
Received: 14 December 2017; Accepted: 13 February 2018; Published: 15 February 2018
Abstract: The standard of treatment for botulism, equine antitoxin, is a foreign protein with associated
safety issues and a short serum half-life which excludes its use as a prophylactic antitoxin and makes
it a less-than-optimal therapeutic. Due to these limitations, a recombinant monoclonal antibody
(mAb) product is preferable. It has been shown that combining three mAbs that bind non-overlapping
epitopes leads to highly potent botulinum neurotoxin (BoNT) neutralization. Recently, a triple human
antibody combination for BoNT/A has demonstrated potent toxin neutralization in mouse models
with no serious adverse events when tested in a Phase I clinical trial. However, a triple antibody
therapeutic poses unique development and manufacturing challenges. Thus, potentially to streamline
development of BoNT antitoxins, we sought to achieve the potency of multiple mAb combinations in
a single IgG-based molecule that has a long serum half-life. The design, production, and testing of a
single tri-epitopic IgG1-based mAb (TeAb) containing the binding sites of each of the three parental
BoNT/A mAbs yielded an antibody of nearly equal potency to the combination. The approach taken
here could be applied to the design and creation of other multivalent antibodies that could be used
for a variety of applications, including toxin elimination.
Keywords: bi-epitopic; tri-epitopic; multivalent antibody; recombinant monoclonal antibody;
botulinum neurotoxin; antitoxin; botulism; mouse neutralization assay; negative-stain electron
microscopy; kinetic-exclusion analysis
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Key Contribution: A tri-epitopic antibody was engineered using the variable regions of
three IgG antibodies with non-overlapping epitopes to botulinum neurotoxin. The resultant
tri-epitopic antibody virtually recapitulated the neutralization activity of a combination of the three
IgG antibodies.
1. Introduction
Botulism, a disease caused by botulinum neurotoxin (BoNT) intoxication, is characterized by
flaccid paralysis, which if not rapidly fatal requires prolonged hospitalization in an intensive-care unit
and mechanical ventilation. The mainstay of clinically proven treatment for botulism is therapeutically
administered antitoxin, made by the immunization of human volunteers or by hyperimmunizing
horses. Equine antitoxin [1,2] and human immune globulin [3,4] are currently used to treat adult
and infant botulism, respectively. Human botulism-immune globulin is produced by plasmaphersing
immunized laboratory personnel who are at risk of exposure to BoNT, and its production is not scalable.
The current generation of equine antitoxin (BAT) is a Fab’2 polyclonal antibody that is not renewable,
has associated hypersensitivity reactions, including cardiac arrest and serum sickness, and has a short
serum half-life resulting in the potential for the relapse of botulism after treatment [5,6]. An alternative
to serum-derived antitoxins is recombinant monoclonal antibody (mAb)-based antitoxin. While single
mAbs do not neutralize BoNT with the requisite potency, combinations of two mAbs increase potency
over a single mAb, with more potent neutralization seen with a combination of three mAbs binding
non-overlapping epitopes [7].
We have generated a series of combinations of three mAbs that bind all toxin subtypes tested
of BoNT/A, /B, /C, /D, /E, /F or /HA and that result in highly potent BoNT neutralization in
mice [7–9]. The BoNT/A three-mAb combination (NTM-1631, formerly XOMA 3AB) has been tested
in a Phase 1 clinical trial with no serious adverse events reported [10] and clinical development of the
antibody combinations for other serotypes is ongoing (NCT02779140, B and NCT03046550, C/D). This
oligoclonal strategy results in a highly potent drug for therapeutic and prophylactic use. However,
a challenge for antibody combination therapeutics is the need to individually manufacture each
component, combine them into a compatible formulation, and then assess the quality and stability of
each component in the mixture individually and in combination. For example, a drug to treat the three
most common serotypes (A, B and E) of BoNT would consist of nine antibodies that would need to be
individually produced, purified, co-formulated, and qualified. As more serotypes are covered in the
final drug product, the complexity of the product and the necessary analytics increases. An alternative
would be to develop a single antibody-based molecule capable of binding multiple BoNT epitopes
that could recapitulate the potency of mAb combinations.
Here, we show that such single bi-epitopic mAbs (BeAb) and tri-epitopic mAbs (TeAb) can be
generated that have similar BoNT binding and neutralization as the combination of two or three
BoNT/A mAbs. Design of the TeAb was informed by first designing and testing a bi-epitopic antibody
(BeAb) based on dual-variable domain (DVD) mAbs [11]. The BeAb and TeAb were designed to contain
a single human Fc to ensure a long serum half-life. Such multi-specific mAbs may offer an alternative
to mAb combinations as antitoxins, taking advantage of the synergistic effect of several mAbs in vivo
and simplifying production, analysis, and preclinical and clinical development by making a single
molecular entity.
2. Results and Discussion
2.1. Design of Bi-Epitopic (BeAb) and Tri-Epitopic Antibodies (TeAb)
The bi-epitopic antibody (BeAb, Figure 1A) was designed based on the DVD construct previously
described [11] and contains the variable domains of mAbs 2G11 [12] and CR2 [13] connected to
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human IgG1/kappa constant domains (Figure 1). 2G11 binds an epitope on the BoNT/A light-chain
domain-translocation domain (LC-HN) and CR2 bind an epitope on the N-terminal subdomain (HCN)
of the BoNT/A binding domain (HC) [14]. The tri-epitopic antibody constructs (TeAbs) were designed
based on the BeAb format, as shown in Figure 1. For these constructs, the RAZ1 mAb [13] variable
regions were either added as a variable fragment (Fv) to the N-terminus of the BeAb or as single chain
Fv fused to either the C-terminus of the kappa constant domain (TeAb-K) or to the C-terminus of the
Fc CH3 domain (TeAb-H). RAZ1 binds an epitope on the C-terminal subdomain (HCC) of the BoNT/A
binding domain (HC) [14].
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Figure 1. Cartoon of bi-epitopic antibody (BeAb) and three different V-domain arrangements of
tri-epitopic antibody (TeAb) formats. The BeAb has the 2G11 Fv as the most external Fv while the CR2
Fv is internal. The three TeAbs are based on the BeAb Fv configuration with the addition of the RAZ1
Fv to the C-terminus of the CR2 V-domains in the BeAb (TVD) or as a single-chain Fv (scFv) fused to
either the C-terminus of the kappa constant domain (TeAb-K) or the C-terminus of the Fc CH3 domain
(TeAb-H).
2.2. Initial Characterization of the BeAb
The BeAb was expressed from stably transfected CHO cells and purified by Protein G affinity
chromatography with yields of approximately 10 mg/L of culture supernatant. Under non-reducing
conditions, the BeAb ran at the expected size of approximately 200 kDa, larger than the predicted size
of the 150 kDa 2G11 and CR2 IgG, and smaller than the TeAb (Figure 2). Under reducing conditions,
the BeAb light chain with the additional V-domain (Vk) and heavy chain with the additional V-domain
(VH) ran at the expected sizes (37.5 kDa and 62.5 kDa, respectively).
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Figure 2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of BeAb,
and TeAb-K. Purified BeAb, IgG, and TeAb-K were run under non-reducing (lane 1–5; Lane 1: BeAb;
Lane 2: RAZ1 mAb; Lane 3: CR2 mAb; Lane 4: 2G11 mAb; Lane 5: TeAb-k) or reducing (lane 7–11;
Lane 7: RAZ1 mAb; Lane 8: CR2 mAb; Lane 9: 2G11 mAb; Lane 10: TeAb-k; Lane 11: BeAb) conditions.
MW makers (lane 6) are at 260, 160, 110, 80, 60, 50, 40, 30, 20 kDa.
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2.2.1. Affinity of the BeAb for Botulinum Neurotoxin (BoNT/A)
Solution monovalent equilibrium dissociation constants (KD) of 2G11 and CR2 binding sites of
the BeAb for antigen were measured using flow fluorimetry in a KinExA (Sapidyne Instruments Inc.,
Boise, ID, USA) and specific recombinant LC-HN and HCN domains, respectively (Figure S1A). The
use of the domains allows accurate measurement of the monovalent KD of one of the binding sites
without the influence of binding of the second binding site. The BeAb bound the 2G11 epitope with
an affinity comparable to the affinity of the parental 2G11 IgG (KD 2G11 IgG = 1.1 × 10−11 M and KD
BeAb 2G11 binding site = 2.11 × 10−11 M, Table 1). In contrast, the BeAb bound the CR2 binding site
with a KD of 1.0 × 10−8 M, 38-fold higher (lower affinity) than the CR2 IgG. The lower affinity was
largely the result of a 10-fold slower association rate (kon), likely due to steric hindrance from the 2G11
binding site (Figure 1) [15]. The affinities of the BeAb CR2 and 2G11 binding sites were also measured
for the BoNT/A1 holotoxin using flow fluorimetry in a KinExA. In the case of holotoxin, different
dimer, trimer or tetramer BeAb states can exist, for example binding of a single BeAb to holotoxin at
a single binding site (affinity), binding at both binding sites (avidity) and crosslinking of holotoxin
(avidity) (Figure S1C). Use of single mAb CR2 or 2G11 capture for the KinExA measurement, however,
ensures that the measurement reflects the impact of these different binding modes specifically on the
CR2 or 2G11 binding sites.
Table 1. Affinities and binding kinetics of the BeAb, TeAb-K and IgG for epitope specific botulinum
neurotoxin (BoNT/A1) domains and BoNT/A1 holotoxin as measured by KinExA.
BoNT/A1 Domain BoNT/A1 Holotoxin
mAb KD (pM) kon (106 M−1s−1) koff (10−6 s−1) KD (pM) kon (106 M−1 s−1)
koff
(10−6 s−1) c
HCN (CR2 epitope)
CR2 263.49 (325.94–171.09) a 4.681 (6.081–3.514) a 1234 8.84 (13.39–5.31) 3.650 (2.988–4.417) 32.27
BeAb b 10,040 (12,760–6790) 0.3986 (0.4957–0.3463) 4002 4.73 (6.31–3.44) 0.7907 (0.8688–0.7181) 3.740
TeAb-K 22,620 (27,550–15,540) 0.1563 (0.1716–0.1429) 3536 2.57 (4.60–1.02) 1.138 (1.290–0.992) 2.924
LC-HN (2G11 epitope)
2G11 11.11 (13.75–8.46) 0.6317 (0.7363–0.5383) 7.018 11.41 (15.28–8.23) 0.5027 (5.514–4.559) 5.736
BeAb 21.13 (25.37–16.23) 0.3937 (.4378–.3525) 8.320 12.78 (21.52–6.62) 2.346 (2.927–1.842) 29.98
TeAb-K 25.79 (29.75–22.21) 0.2616 (0.2739–0.2508) 6.747 2.59 (5.78–0.57) 2.128 (2.779–1.615) 5.512
HCC (RAZ1 epitope)
RAZ1 1.33 (1.92–0.813) 10.02 (14.61–6.222) 13.33 1.73 (1.96–1.53) 15.89 (16.84–15.03) 27.49
TeAb-K 25.53 (45.03–12.23) 2.115 (2.331–1.919) 53.99 15.18 (25.62–8.10) 1.186 (1.284–1.092) 18.00
a 95% confidence interval; b the entire heavy chain was used for these measurements; c koff was calculated from kon
and KD, therefore no CI is provided.
Using holotoxin, the BeAb bound the 2G11 binding site with a KD approximately the same as
the 2G11 IgG (KD 2G11 IgG = 1.14 × 10−11 M and KD BeAb 2G11 binding site = 1.28 × 10−11 M), as
shown in Table 1. The approximately 2-fold lower KD of the BeAb for holotoxin compared to CR2
IgG (higher affinity) than the CR2 IgG (Table 1) results from an almost 10-fold slower dissociation rate
constant (koff), likely reflecting avid binding from the 2G11 binding site. Differences in the binding of
antibodies to the HCN domain vs. holotoxin reflect the fact that the recombinant domain is not a perfect
mimic of the CR2 epitope in the holotoxin [14]. These studies indicate that the BeAb recapitulates the
high-affinity binding of CR2 and 2G11 in a single IgG-like molecule.
2.2.2. In Vitro Functional Effects of the BeAb Compared to 2G11 and CR2 IgG
To ensure that the BeAb recapitulated the functional activity of CR2 and 2G11 in vitro, the ability
of the BeAb, CR2 IgG, 2G11 IgG and the combination of CR2 + 2G11 IgG to prevent uptake of BoNT/A
into neurons and cleavage of SNAP25 was compared (Figure 3). CR2 IgG blocked neuronal uptake
of BoNT/A and, as a result, SNAP-25 cleavage, while 2G11 IgG did not block uptake and was not as
potent as CR2 in inhibiting SNAP-25 cleavage. The BeAb recapitulated this effect of CR2, blocking
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BoNT/A uptake and more potently inhibiting SNAP-25 cleavage than 2G11 alone. CR2 binds to an
HC epitope that blocks the ability of BoNT/A to bind to its receptor [16].Toxins 2018, 10, x FOR PEER REVIEW  5 of 18 
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(A) Ability of the indicated antibody to block uptake of BoNT/A into rat hippocampal primary neurons.
Mixtures of BoNT/A1 and the indicated antibody shown were mixed, incubated with neurons for
30 min, stripped from the cell surface, the cells permeabilized and intra-neuronal BoNT/A detected
using mAb(s), indicated. (B) Ability of the indicated antibody to block SNAP-25 cleavage. BoNT/A1
(1 nM) and the indicated antibody shown were mixed, incubated with neurons for 30 min, the cells
lysed, and the lysate run on SDS-PAGE followed by Western blotting using an antibody specific
for SNAP-25.
2.3. Initial Characterization of the TeAb
The TVD, TeAb-K and TeAb-H were expressed from stably transfected CHO cells and purified by
Protein G affinity chromatography with yields of approximately 5–10 mg/L of culture supernatant.
The TVD and TeAb-H could not be purified to greater than 80% purity and the TVD also had a tendency
to aggregate. These constructs were not studied further. Under non-reducing conditions, the TeAb-K
ran close to its predicted size of 250 kDa (the 200 kDa of the BeAb component plus two 25 kDa scFv)
(Figure 2). Under reducing conditions, four bands of approximately 62.5 kDa would be expected, two
representing the 2G11 VH, the CR2 VH and the CH1, CH2 and CH3 domains, and two representing the
2G11 Vk, the CR2 Vk, the Ck and the VH and Vk of RAZ1.
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binding sites (avidity) and crosslinking of holotoxin (avidity) (Figure S1D). Use of single mAb CR2,
2G11 or RAZ1 capture for the KinExA measurement, however, ensures that the measurement reflects
the impact of these different binding modes specifically on the CR2, 2G11 or RAZ1 binding sites.
Using recombinant BoNT domains, the TeAb-K bound the 2G11 and CR2 epitopes with KD
comparable to the KD measured for these epitopes in the BeAb (Table 1). The TeAb-K bound the RAZ1
epitope with high affinity but with a KD approximately 20-fold higher (lower affinity) than the RAZ1
KD (KD RAZ1 IgG = 1.33 × 10−12 M and KD TeAb-K RAZ1 binding site = 2.55 × 10−11 M (Table 1).
This may result from the conversion of the RAZ1 from a Fab in the IgG to a scFv in the TeAb-K [17].
The TeAb-K bound BoNT/A holotoxin with very high affinity at each of the three binding sites (RAZ1,
CR2 and 2G11) with KD ranging from 1.51 × 10−11 M to 2.57 × 10−12 M. These studies indicate that
the TeAb-K recapitulates the high-affinity binding of the RAZ1, CR2 and 2G11 binding sites in a single
IgG-like molecule.
2.4. BeAb and TeAb-K Neutralization of BoNT/A In Vivo
The potency of the BeAb and TeAb in neutralizing BoNT/A in the mouse-neutralization assay
(MNA) was compared to the potency of individual mAbs 2G11, CR2 and RAZ1, the combination of
2G11 and CR2 IgG and the combination of 2G11 + CR2 + RAZ1 IgG. Fifty µg of each of individual mAbs
completely neutralized between 20 and 100 mouse LD50 in the MNA [18] (Figure 4). A combination
of CR2 + 2G11 IgG (50 µg total antibody, 25 µg of each mAb) was approximately 100 times more
potent than either single IgG, completely protecting mice challenged with 10,000 LD50 of BoNT/A
(Figure 4). The BeAb (50 µg) was comparable in potency to the CR2 + 2G11 IgG combination, with
9/10 mice surviving challenge with 10,000 LD50 of BoNT/A compared to 10/10 mice surviving given
the CR2 + 2G11 IgG combination. This result is consistent with previous studies of other BoNT/A
mAbs showing mAb pairs neutralize BoNT/A much more potently than individual mAbs [7]. At a
40,000 LD50 challenge with BoNT/A, only 0/10 and 2/10 mice survived for mice receiving the BeAb
or the 2G11 + CR2 IgG combination, respectively (Figure 4). In contrast, 50 µg of either the TeAb
or the 50 µg total of the combination of 2G11 + CR2 + RAZ1 (16.6 µg of each mAb) IgG completely
protected mice challenged with 40,000 BoNT/A LD50. To determine the potency of these antibodies,
decreasing amounts of either the TeAb or the 2G11 + CR2 + RAZ1 IgG combination were mixed with
40,000 LD50 of BoNT/A and survival after five days was determined. The combination of 2G11 + CR2
+ RAZ1 IgG or the TeAb were approximately 100-fold and 20-fold more potent than the 2G11 + CR2
IgG combination and approximately 200-fold and 40-fold more potent than the BeAb, respectively
(Figure 4). The ED50 for the 2G11 + CR2 + RAZ1 IgG combination and TeAb vs. 40,000 BoNT/A LD50
were approximately 0.6 µg and 2.5 µg respectively, making the TeAb approximately four-fold less
potent than the 2G11 + CR2 + RAZ1 IgG combination (Figure 4).
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Figure 4. Antibody p tency as ssessed by t ouse neutr lization assay (MNA). Panel above:
relative potency of the BeAb and TeAb compared to CR2, 2G11 and RAZ1 IgG and their combinations.
50 µg of CR2, 2G11 or RAZ1 mAb, 25 µg each of the combination of CR2 + 2G11, 16.6 µg each of the
combination of CR2 + 2G11 + RAZ1, 50 µg of BeAb or 50 µg of TeAb were mixed with the indicated
amount of BoNT/A1 complex and injected intr perit neal y into cohorts of 10 mice, n the number
of mice surviving at 5 days was determined. Panel below: relative potency of the TeAb compared
to the combination of 2G11 + CR2 + RAZ1 IgG. 40,000 LD50 of BoNT/A1 was combined with either
the TeAb or an equimolar combination of 2G11 + CR2 + RAZ1 IgG at the amount indicated, injected
intraperitoneally into cohorts of 10 mice and the number of surviving mice was determined at 5 days.
2.5. Mechanism of BeAb and TeAb BoNT/A Neutralization
One mechanism by wh ch polyclonal antibody n utr lizes BoNT is by accelerating its clearance
through the liver by im une complex formation [19]. Negative-stain electron microscopy (NS-EM)
was used to determine if the TeAb formed immune complexes with BoNT/A. For these experiments,
catalytically inactive (ciBoNT/A, 17 nm average diameter) was used for safety reasons [20]. While
the flexibility of the olecules and complexes precluded high-resol tion images, the results provide
insight into the types of complexes formed. In NS-EM, IgG alone exhibits the expected “Y” shape with
an average diameter of 13 nm (Figure 5A). ciBoNT/A appears as a globular shape consistent with
its known X-ray crystal structure [21] (Figure 5B). The three IgG CR2 + RAZ1 + 2G11 + ciBoNT/A
produces complex structures; some unbound IgG are also visible (Figure 5C). The TeAb-K is “Y” shaped,
but with additional domains, and is monodisperse with an average diameter of 20 nm (Figure 5D). The
TeAb-K + ciBoNT/A forms more complex structures consistent with immune complexes containing
what appears to be multiple TeAb-K and ciBoNT/A and with diameters between 26 to >100 nM
Figure 5E).
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Figure 5. Negative-stain electron microscopy (NS-EM) images of TeAb-K immune complexes. Scale
shown in (A) applies to all five panels, insert of each image is an enlargement of a single molecule
or complex in greater detail. (A) RAZ1 IgG; (B) ciBoNT/A; (C) RAZ1 + 2G11 + CR2 + ci BoNT/A;
(D) TeAb-K; (E) TeAb-K + ci BoNT/A.
The ability of the BeAb or TeAb to accelerate the clearance of ciBoNT/A from the circulation
of mice was studied and compared to the effect of 2G11 + CR2 IgG and 2G11 + CR2 + RAZ1 IgG
on ciBoNT/A clearance. These studies were performed by injecting 5000 pg of ciBoNT/A [20] into
mice followed 5 min later by the injection of 10 µg of the BeAb, TeAb or IgG antibody combination
(5 µg of each mAb for the double mAb combination and 3.3 µg of each mAb for the triple mAb
combination) and measuring the serum concentration of ciBoNT/A at serial time points. Both the
BeAb and the combination of CR2 + 2G11 IgG significantly slowed the clearance of ciBoNT/A from
the circulation of mice compared to that of no antibody (Figure 6). We did not collect data at late
enough time points to be able to calculate a BoNT-mAb half-life due to the reduced clearance. In
contrast, both the TeAb-K and the combination of 2G11 + CR2 + RAZ1 IgG increased the clearance of
ciBoNT/A from the circulation of mice compared to the control with no antibody, with the three mAb
combination being more effective than the TeAb at increasing clearance. The two-phased clearance
observed for the TeAb (an initial rapid phase followed by a slower terminal phase) would be consistent
with a fraction of the immune complexes containing three Fc per BoNT (rapid clearance) and a fraction
containing two or less per BoNT (slower clearance). Because of the multiple phases, we were unable to
calculate a half-life for the TeAb-BoNT due to the multiple half-lives present, presumably due to the
heterogeneity of the immune complexes. These clearance results are consistent with those observed
by others. Antibody buffering and a reduction in clearance of antigen has been previously described
for single mAbs binding an antigen and attributed to antigen bound to mAb picking up the long
serum half-life of IgG [22]. Similarly, Mannik et al. [23] found that immune complexes containing
one or two IgG persisted in the circulation, while those with more than two IgG were cleared rapidly.
Montero-Julian et al. also found that IL-6 administered with one or two mAbs had its clearance
reduced approximately 10 fold, and that clearance was returned to the rapid clearance observed for
IL-6 only when three mAbs were administered [24].
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3. t ri ls et s
3.1. esign, Cloning, Expression and Purification of BeAb and TeAb
The BeAb and three different TeAb expression-vector plasmids were constructed using the 2G11,
CR2 or RAZ1- IgG1 N5KG1 expression vectors or their scFv leads in pYD2 vectors (Invitrogen,
Ther o Fisher Scientific, Inc., altham, MA, USA) si ilar to those previously reported [25]. For
Be b construction, the second V-domain genes (Vk and VH gene of 2 11) ere sequentially inserted
into the CR2-Ig expression vector, hich as created using the Ig 1 expression vector 5 1 as
previously reported [12], with sequence verification before transformation into mam alian CHO cells
(ATCC, Manassas, VA, US ). The resulting construct has the 2G11 Vk and VH domains fused to the
C-terminus of the CR2 Vk and VH domains respectively separated by a 14-amino acid linker1 of amino
acid sequence TVAAPSVFIFPPSD for Vk, or linker2 ASTKGPSVFPLAPS for VH. Briefly, the Vk genes
plus a linker were PCR- amplified from the mAb 2G11-IgG1 expression vector N5KG1 [12] using the
following primer pairs:
glIIi raIII t ′ (5′-ATCACAGATCTCTCACCATGAGGGTCCCCGCTCAGCTCCTG
CTCCTGCTGCTCTG CTCCCAGGTGCCCGATG-3′)
DraIIIinBsiWoutVklinker3′primer: (5′-ACTGCTCATCACATCGTGAGAAGATGAAGACAGATGGTG
CAGCCACGGTACGTTTGATTTCC-3′)
The PCR-amplified Vk + linker1 fragment was double cut with BglII and DraIII restriction enzymes
(New England Biolabs, Ipswich, MA, USA), purified and ligated into the mAb CR2-IgG1 expression
vector backbone which was digested and purified similarly. The ligation product was used to transform
E. coli DH5α competent cells, and vector plasmids containing the insertion were purified from the
transformant for DNA sequencing. After sequence verification of the correct 2G11 Vk insertion into
the mAb CR2-IgG1 plasmid from one of the transformants, the resulting vector was used for 2G11 VH
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insertion to create the BeAb expression plasmid. The VH genes with a second linker2 were polymerase
chain reaction (PCR) amplified from the same mAb 2G11-IgG1 expression vector using a different pair
of primers for the VH + linker2 gene fragment:
SalIinMluIoutVH5′primer: (5′-GACCCGTCGACATGGGTTGGAGCCTCATCTTGCTCTTCCTTGT
CGCTGTTGCTACCCGTGTCTTGTCCC-3′)
MluIinNheIout VH3′ tail primer: (5′-GGAGGAGGGTGCCAGACGCGTGACCGATGGGCCCTTGG
TGCTTGCTGAGGAGACGG-3′)
The PCR-amplified VH + linker2 gene fragment was double digested with SalI and MluI restriction
enzymes, purified, and subcloned into the plasmid from the previous step. The resulting plasmid was
digested with same enzyme pairs before ligation and transformation. The ligation products were used
to transform E. coli DH5α competent cells, and new plasmids were prepared from those transformants
for sequencing. Both V-genes of mAb 2G11 and CR2 were confirmed to be in the BeAb expression
vectors, and they were in frame with the leader sequence, and also in frame with the constant domain
gene plus the designed linkers. This confirmation was achieved via sequencing the plasmid from
upstream of the leader sequence and downstream of the constant domain genes using VHfor, VHback,
Vkfor and Vkback primers as previously published [26] and additional primers as listed in Table S1.
Three triepitopic antibodies (TeAbs) were created based on the BeAb construct with the 2G11 and
CR2 V-domain at the N-terminus of the IgG. The third binding site (RAZ1 V-domains) was inserted as
either the innermost tandem V-domains fused to the C-terminus of CR2 V-domains and the N-terminus
of the Ck and CH1 domains (TVD) or as a scFv at the C terminus of the Ck (TeAb-K) or CH3 (TeAb-H)
as illustrated in Figure 1.
For the TVD gene construction, two additional linkers encoding 13 amino acids each were used
to link the CR2 and RAZ1 domain V genes; The amino acid for the Vk linker3 is TVAAPSVFIFSRC
and that for the VH linker4 is ASTKGPSVTRVLS. Linker3 and linker4 genes were added to the RAZ1
V gene via PCR by using the IgG expression plasmid and primer pairs RAZBsiWIlinkerVk5′primer
and Vk3′primer, or RAZNheIlinkerVH5′ primer and VH3′ primer (Table S1). The fragment with
the additional linker was spliced to the BeAb V-genes before subcloning the entire three V-domain
genes back into the IgG expression vector backbone. Briefly, the third VH and Vk fragment for TVD
creation was PCR amplified first from RAZ1 IgG expression plasmid to include all the following:
“BsiWI enzyme restriction site and linker3 and RAZ1 Vk + CK1 genes with SpeI restriction site, or “NheI
restriction site and linker4 and RAZ1 VH gene plus partial CH1 gene and AgeI restriction site”, then
digested one PCR product with BsiWI and EcoRI to obtain a fragment containing the Vklinker3, and
digested the other purified PCR product with NheI and AgeI for a fragment containing the VHlinker4,
and then ligated the fragments sequentially into the BeAb expression plasmid vector that was digested
with same pair of enzymes to obtain the TVD expression plasmid, [12] followed by transformation of
E. coli DH5α with ligation products, and sequence confirmation from individual transformants after
plasmid preparation. All six V-genes of mAbs 2G11, CR2 and RAZ1 were confirmed to be in the TVD
TeAb expression vector, and they were in frame with the leader sequence, and also in frame with the
constant domain gene plus the designed linkers in the correct order. The TeAb expression plasmid was
then used to transform CHO cells using similar procedures as published [26].
For TeAb-K expression-vector construction, the RAZ1 scFv gene was first PCR amplified from
RAZ1-scFv pYD2 yeast expression vector [13], using primer pairs (Table S1) LinkerKspliceRAZ5′primer
and TeAbKEcoRIin3′primer, which encodes partial (16 AA) of an extra linker5 and the stop codon
immediately after the scFv gene plus the restriction sites EcoRI for subcloning. Linker5 is a 20-amino
acid long sequence of SGGSTSGSGKPGSGEGSSGS and was designed to be located between the RAZ1
scFv domain and the C-terminus of the Ck domain. This fragment was than spliced with another
fragment which was PCR amplified from the IgG expression vector using primer pairs (Table S1)
of TeAbKBsiWIin5′primer and RAZ1linkerKsplice 3′primer containing the entire Ck domain gene
and with BsiWI restriction site and partial overlapping (11 AA) linker5 sequence added for splicing.
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After splicing PCR amplification, the entire fragment was double digested with BsiWI and EcoRI, then
ligated into the BeAb expression plasmid backbone which had been digested with the same enzymes
and purified. After ligation, the product was used to transform E. coli DH5α, and plasmid purified
from individual transformants for sequence confirmation using primer TeAbKscfvSeqprimer.
For TeAb-H expression, vector construction was also performed using a three-step PCR and
splicing strategy. The RAZ1 scFv gene was first PCR amplified from RAZ1-scFv pYD2 yeast expression
vector, using primer pairs (Table S1) LinkerHspliceRAZ5′primer and TeAbHBamHIin3′primer, which
also encodes a partial (16 amino acids) linker5 and a stop codon immediately after the scFv gene, plus
the restriction sites BamHI at the 3′ end for subcloning. This fragment was then spliced with another
fragment which was PCR amplified from the same IgG expression vector using primer pairs (Table S1)
of TeAbHSmaIin5′primer and RAZlinkerHsplice 3′primer containing the partial CH3 domain gene
and with a SmaI restriction site at the 5′ end. The splicing product was used to transform E. coli DH5α,
and plasmid prepared from individual transformants for sequence confirmation using sequencing
primer ForTeAbscfvseq and primer4scfvconfirm.
All V-genes and each linker gene sequence in the BeAb or TeAb expression vectors were confirmed
to be as designed, and in frame with the leader sequence and with the constant domain gene.
Sequencing of the plasmid was performed from upstream of the leader sequence and downstream
of the constant domain genes as described above. Stably-transfected CHO DG44 cells were selected
using the G418 (Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) resistant marker as
previously described [7]. The transfected cells were cultured and expanded into 1L spinner flask
for BeAb or TeAb production. Supernatant from the cell cultures were collected and filtered with
0.22 µm filters before loading on to HiTrap Protein G HP columns (GE Healthcare, Little Chalfont, UK)
for purification as previously described [12,13]. Purified BeAb or TeAb were quantified via sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and A280 measurement and used
immediately or stored at −80 ◦C prior to characterization.
3.2. Binding Affinity Determinations Using KinExA Analysis
Equilibrium dissociation constants (KD) and kinetic association and dissociation rate constants
(kon, koff) of BeAb and TeAb for holotoxin and for specific recombinant BoNT domains were measured
using a KinExA 3200 flow fluorimeter (Sapidyne Instruments Inc., Boise, ID, USA) as previously
described [13,27]. Binding affinity assays were performed in duplicate; equilibrium titration data were
fit to a 1:1 reversible binding model using KinExA Pro Software (version 4.2.12, Sapidyne Instruments,
Boise, ID, USA, 2016) to determine the KD. The exponential decrease in the concentration of free
antigen as a function of time was fit to a standard bimolecular rate equation using the KinExA Pro
software to determine the kon. The koff was calculated from the product of kon × KD.
A schematic of the KinExA method is provided in Supplemental Figure S1. Solution interactions
of BeAb and TeAb with specific BoNT domains are monovalent, and four binding states exist at
equilibrium of which only the free domain can be captured by the mAb-coupled beads in the flow
cell. Solution interactions of BeAb and TeAb with holotoxin are multivalent, and many more binding
states with free epitopes can form and be captured by the beads, including complexes formed by avid
binding and crosslinking.
3.3. Inhibition of BoNT/A1 Cellular Uptake and SNAP25 Substrate Cleavage in Primary Neurons by IgG1
or BeAb
Rat hippocampal primary neurons were prepared as described [28]. BoNT/A1 cellular uptake
inhibition by each individual mAb or BeAb or the combination of two mAbs were tested in 12- to
14-day-old primary neurons using BoNT/A1 toxin only without mAb as positive toxin entrance control.
The treated neurons were harvested and divided into two parts, one for BoNT/A1 entrance visual
inspection using confocal microscope, the other for SNAP25 digestion detection with SDS-PAGE-based
endopeptidase assay, as published [29].
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For microscopy, internalized BoNT/A1 toxin inside the neuron was detected using mAb
4E17.1 [26] and DyLight 488 conjugated goat anti-human IgG (H + L, Jackson ImmunoResearch,
Catalog #109-485-003), then recorded with a confocal microscope (Nikon Eclipse C1si True Spectral
Imaging, Nikon Instruments, Inc., Melville, NY, USA). Briefly, 10 nM BoNT/A1 (Metabiologics Inc.,
Madison, WI, USA) was mixed with 100 nM or less of individual mAb CR2 or 2G11 IgG1, an equimolar
combination of CR2 and 2G11, or 100 nM or less BeAb in high potassium buffer (87 mM NaCl,
56 mM KCl, 1.5 mM KH2PO4, 8 mM NaHPO4, 1 mM CaCl2, and 0.5 mM MgCl2) for 30 min at
room temperature. Each mixture was then added to individual wells of 12- to 14-day-old primary
neurons incubated at 37 ◦C for 30 min before phosphate-buffered saline (PBS) washing and 10% goat
serum blocking of non-specific binding. BoNT/A1 without antibody was used as a positive uptake
and cleavage control. After fixing the treated neurons with freshly prepared 4% paraformaldehyde,
permeabilization of fixed cells was done by incubation with 0.2% Triton X-100. The neurons were
sequentially incubated with 1 µg/mL of mAb 4E17.1 for two hours and 5 µg/mL of goat anti-human
IgG secondary Ab for one hour at room temperature. A polyclonal guinea pig antibody for vesicular
glutamate transporter 1 (Millipore, AB5905), a synaptic vesicle marker, was also used to show the
location of presynaptic terminals when necessary. After washing, the samples were mounted and sent
for imaging analysis.
In the SDS-PAGE-based endopeptidase assay, the amount of intact and cleaved SNAP25 from the
treated neurons was detected with antibody to SNAP25. Briefly, neurons treated with test antibody
(CR2, 2G11 or BeAb) at the concentration of 0–4 nM mixed with 1 nM of BoNT/A1 in the Opti-MEM
media were monitored. Cells were scraped off the dishes and protein was extracted by using radio
immunoprecipitation assay (RIPA) lysis and extraction buffer with proteinase inhibitors (Thermo
Scientific). After centrifugation at 13,400 × g for 20 min, the supernatant was then collected and
protein concentration was determined by the absorbance at the 280 nm. The extracted protein from
the cell lysate was loaded onto a 4–20% SDS-PAGE gradient gel for electrophoresis and the separated
proteins were then transferred onto a polyvinylidene difluoride membrane (iBlot gel transfer device,
Life Technologies). The membrane was blocked with 5% fat-free milk, then immunoblotted overnight
with a primary antibody against SNAP-25 (Santa Cruz Biotechnology Inc., Dallas, TX, USA) at 4 ◦C,
followed by incubation with horseradish peroxidase-conjugated anti-mouse secondary antibody
(Jackson Immuno Research, West Grove, PA, USA) and visualization using SuperSignal West Femto
kit (Thermo Scientific, Grand Island, NY, USA) and autoradiography using Kodak film (Kodak Co.,
Rochester, NY, USA). The scanned images were also analyzed by using NIH Image J software for
semi-quantitation followed by Western blotting (Figure 3B).
3.4. Mouse Neutralization Assay of BoNT/A1 by IgG, BeAb or TeAb
The United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
Institutional Animal Care and Use Committee (IACUC) approved the animal care and use protocol
to conduct the animal studies described in this sub-section and in Section 3.5, below. Research
was conducted under an IACUC approved protocol in compliance with the Animal Welfare Act,
Public Health Service (PHS) Policy, and other federal statutes and regulations relating to animals and
experiments involving animals. The facilities where this research was conducted are accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC/I)
and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National
Research Council, 2011. The specific national regulations and guidelines to which this animal care and
use protocol adheres are the following: (1) 7 United States Code (USC), Sections 2131–2159, Chapter 54
“Animal Welfare Act”, and (Code of Federal Regulations (CFR)), Chapter 1, Subchapter A, Parts 1–4
“Animal Welfare Regulations”; (2) Health Research Extension Act of 1985, Public Law 99–158 “Animals
in Research” and the PHS Policy in Humane Care and Use of Laboratory Animals; (3) Biosafety in
Microbiological and Biomedical Laboratories, 5th Edition, National Institutes of Health (NIH), Human
and Health Services Publication (Centers for Disease Control and Prevention (CDC)) 21–112. Studies
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performed at USAMRIID also complied with (1) Army Regulation 40–33 “The Care and Use of Animals
in Department of Defense (DOD) Research, Development, Test and Evaluation or Training Programs”
and (2) DOD Instruction 3216.01 “Use of Animals in DOD Programs”. DOD uses “The Guide for the
Care and Use of Laboratory Animals”, 8th Edition, Institute for Laboratory Animal Research, National
Research Council, as a guideline for evaluation and accreditation of program and it is based on the
actual national regulations and guidelines for animal care and use programs. The animals used in
this study were euthanized using carbon dioxide gas following the American Veterinary Medical
Association (AVMA) Guidelines on Euthanasia.
All procedures involving animals performed at the United States Department of Agriculture
(USDA) were reviewed and approved by the Institutional Animal Care and Use Committee of the
USDA, Western Regional Research Center. Animal use protocol for BoNT mouse bioassays (Protocol
#15-8) was approved by the Western Regional Research Center Institutional Animal Care and Use
Committee (WRRC-IACUC) on 27 July 2015.
BeAb, TeAb, individual IgGs of 2G11, CR2 or RAZ1, or a combination of two or three IgGs
(1–50 µg total antibody per mouse) were added to an indicated number of mouse LD50 of BoNT/A1
holotoxin (Metabiologics Inc. Madison, WI, USA) in gelatin phosphate buffer (pH 6.5) and incubated
at room temperature for 30 min. For the mAb pairs, antibody was added in a 1:1 ratio; for triple mAb
combinations, antibody was added in a 1:1:1 ratio. The mixtures were injected intraperitoneally (i.p.)
into groups of 10 female (CD-1 mice weighing 16–22 g upon receipt at USAMRIID, or CFW, Swiss
Webster at USDA Western Regional Research Center). Mice were observed at 4–8 h intervals after toxin
challenge. Mouse survival was recorded for 5 days after injection.
3.5. Estimation of TeAb-K Complex Size and Composition Using Negative-Stain Electron Microscopy (NS-EM)
Purified antibody as individual IgG or BeAb or TeAb, ciBoNT/A, or antibody-toxin complexes
were applied to glow-discharged 400 mesh carbon-coated copper grids, washed, stained with 0.75%
(w/v) uranylformate, and aspirated to dryness as reported [30]. Images were taken on a Tecnai T12
electron microscope (FEI Company, Hillsboro, OR, USA) equipped with a LaB6 filament and operating
at a 120-kV acceleration voltage. Micrographs were recorded using a 4K charge-coupled device camera
(UltraScan 4000, Gatan Inc. Pleasanton, CA, USA), where one pixel equals 2.21 Å on the specimen.
3.6. Pharmacokinetic Studies of ciBoNT/A in the Presence of Antibodies
Groups of three Swiss Webster female mice (Charles River, Portage MI, weights 19–20 g) were
injected intravenously (iv) via the lateral tail vein with 5000 pg ciBoNT/A and 10 µg of mAb (IgG1,
BeAb or TeAb) per mouse at indicated times. MAbs were diluted in PBS (pH 7.2). Blood was collected
from the submandibular site into serum collection tubes with gel separators (BD Biosciences). Samples
were incubated on ice for at least 30 min before centrifugation at 3000× g for 10 min to separate sera
from the cellular fraction. Sera were aliquoted and stored at −80 ◦C prior to analysis.
The concentration of ciBoNT/A in sera was determined by an electrochemiluminescence (ECL)
ELISA using a SECTOR Imager 2400 (MSD, Gaithersburg, MD, USA). ECL was performed as described
previously with slight modification [31]. Briefly, 96 well plates were coated with anti-BoNT/A mAb
5A20.4 at 2 µg/mL and incubated overnight at 4 ◦C. Plates were blocked with tris-buffered saline
(TBS) Tween with 3% milk (block buffer). Toxin standards were prepared in 50% normal mouse sera
(MP Biomedicals, Santa Ana, CA, USA) and sera samples were diluted in PBS (1:1). Sample plates
were incubated at 37 ◦C for 1 h. After washing, 30 µL of 2 µg/mL rabbit polyclonal anti-BoNT/A
(Metabiologics, Madison, WI, USA) was added and the plates were incubated for 1 h at 37 ◦C. The
plates were then washed and incubated for 1 h with 30 µL of a 1:1000 diluted Sulfo-Tag labeled
anti-rabbit antibody conjugate, followed by Reading buffer (MSD). The biologic half-life of toxin or
mAbs was determined by calculating two-phase exponential decay over time using the GraphPad
Prism statistics software (Version 7.0, Graphpad Prism, Inc., La Jolla, CA, USA).
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4. Discussion
We have partially reproduced within four-fold the increased BoNT neutralization potency of
double or triple mAb combinations in a single IgG-based molecule by creating biepitopic (BeAb) and
triepitopic (TeAb) antibodies. The BeAb was designed based on the previously described dual variable
domain (DVD) IgG [11]. Using epitope specific BoNT/A domains, it was shown that the affinity of the
outer variable domains maintained the same affinity for BoNT/A as the parental IgG 2G11, while the
inner variable domains had an approximately 40-fold lower affinity compared to the parental CR2
IgG due primarily to a 12-fold slower kon. Such a decrease in affinity due to a reduction in kon for
the inner-variable domains has been previously reported for a DVD binding TNFα [15] and could be
partially overcome by linker redesign. Regardless, affinity of both the 2G11 and CR2 binding sites for
BoNT/A was comparable to that of the parental IgG, despite the lower affinity for the CR2 binding
site in the epitope specific domain. While the kon for the CR2 binding site for BoNT/A was 4.6-fold
slower than the CR2 IgG, this was more than compensated by a 8.6-fold slower koff for the CR2 site
in the BeAb compared to CR2 IgG. These findings suggest that the BeAb avidly bound to BoNT/A,
either simultaneously binding a single BoNT/A at both the 2G11 and CR2 epitopes or cross-linking
multiple BoNT/A molecules. This is likely due to the flexibility of the 2G11 and CR2 binding sites in
the DVD format [32]. The BeAb blocked the uptake of BoNT/A and cleavage of SNAP25 in neuronal
cells, and recapitulated the potency of the combination of the two parental IgGs in a mouse-protection
assay, with neutralization ED50 between 20,000 and 40,000 LD50 with a 50 µg/mouse total antibody
dose. The potency of the BeAb, like the mAb pair combination, was approximately 100 times greater
than the individual mAbs.
Three TeAb constructs were designed based on the successful BeAb structure. Of these, only
the TeAb-K, with the RAZ1 scFv fused to the C-terminus of the kappa light-chain constant domain
was produced with sufficient purity and quantity for detailed characterization. The TeAb-K had
comparable affinity for the 2G11 and CR2 epitopes as the BeAb as measured by the epitope specific
domains. The affinity of the TeAb for the RAZ1 epitope was approximately 19-fold lower than RAZ1
IgG, likely due to conversion to the scFv format. Affinity for BoNT/A at the 2G11 and CR2 epitopes
were 5.4 and 3.4 times higher than for the 2G11 and CR2 IgG and the reduction of affinity of the
RAZ1 scFv was only 8.8-fold. These data, like for the BeAb, suggest avid binding of the TeAb to
BoNT/A. The TeAb-K had an ED50 for a 40,000 LD50 dose of BoNT/A of approximately 2.5 µg, or
about 40-fold more potent than the BeAb and 20-fold more potent than the combination of mAbs 2G11
and CR2. The TeAb, however, was approximately four-fold less potent in BoNT/A neutralization than
the combination of 2G11 + CR2 + RAZ1 IgG.
mAb combinations can synergize by a number of different mechanisms to neutralize BoNT. First,
binding of multiple mAbs can interfere with multiple steps in the intoxication pathway, such as
receptor binding and cell entry, endosomal translocation or intracellular catalysis [33]. Second, binding
of multiple mAbs can create an avid antigen leading to an increase in mAb functional affinity [7].
Third, binding of multiple mAbs leads to rapid Fc-mediated clearance via the liver [19]. Finally, the
large size of immune complexes likely slows the trafficking of BoNT to its site of action. In the case of
mAb pairs and the BeAb, BoNT clearance is in fact reduced compared to BoNT only, indicating that
other mechanisms such as blockade of multiple BoNT receptor biding sites or slowing the trafficking of
BoNT to its site of action. In contrast, the triple mAb combination and TeAb accelerate BoNT clearance,
likely explaining why these molecules are more potent. Rapid antigen clearance requires the binding
of at least three Fc to antigen [23,24]. This clearly occurs with the triple mAb combination leading to
rapid clearance. In contrast, based on the pharmacokinetic curve, it appears that only a fraction of the
TeAb binds in that manner, likely explaining the four-fold reduction in potency.
Multifunctional antibodies have entered preclinical as well as clinical development. Despite the
significant progress on bi-specific antibody constructs [11,34–38], however, there are fewer reports
of tri-specific antibodies [39–44]. The majority of the bi-specific constructs and all of the trispecific
antibodies in these reports target at least two distinct proteins rather than three distinct epitopes on
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the same protein, as reported here. A recent report, however, describes a tri-specific antibody binding
three distinct binding sites on the HIV-1 envelope. In this study, multi-specificity increases potency
and allows broader clade neutralization and higher potency than individual mAbs [45]. Similarly, the
tri-epitopic mAb reported here has greater potency than single mAbs and should provide broader
subtype binding than any individual mAb. Such tri-epitopic mAb could have great utility in the
rapid clearance and neutralization of a range of toxins besides BoNT, such as ricin, and other toxic
molecules. Whether such bi-epitopic or tri-epitopic molecules prove to be reliable alternatives to
antibody combinations remains to be proved. Potential challenges include immunogenicity due to
linkers, decreased stability or propensity for aggregation, due to non-IgG like V-domain pairings and
reduced serum half lives and potency compared to antibody combinations.
5. Conclusions
In summary, we have described how the synergy observed by combining three BoNT/A mAbs
can almost be reproduced in a single tri-epitopic IgG-like molecule. Potency is increased more than
2000-fold compared to single mAbs. While it is unproven as to how easily such triepitopic antibodies
can be developed as therapeutics, they may provide an alternative to mAb combinations for the
treatment and prevention of botulism.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/10/2/84/s1,
Figure S1: Binding affinity measurement of the BeAb and TeAb by flow fluorimetry, Table S1: Primers used
for TeAb construction and sequencing confirmation.
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